Kaken Pharmaceutical
Clinical trials sponsored by Kaken Pharmaceutical, explained in plain language.
A Japanese pharmaceutical company focused on dermatology and anti-inflammatory drugs.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
Liver health may change how drug KP-001 works in the body
Knowledge-focused CompletedThis completed Phase 1 study tested a single 50 mg dose of the drug KP-001 in 24 adults, some with healthy livers and others with different levels of liver impairment. The goal was to see how liver function affects the drug's levels and safety in the body. Results could help guid…
Phase 1 • Sponsor: Kaken Pharmaceutical • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:56 UTC
-
New drug KP-001 put to the heart safety test
Knowledge-focused CompletedThis study checks whether a new drug called KP-001 affects the heart's electrical activity (QT interval) in 40 healthy adults. Participants receive single doses of KP-001, a placebo, or moxifloxacin (a control drug known to affect the QT interval) in random order. The goal is to …
Phase 1 • Sponsor: Kaken Pharmaceutical • Aim: Knowledge-focused
Last updated Jun 26, 2026 18:08 UTC
-
New drug KP-001 tested for interactions with common meds
Knowledge-focused CompletedThis completed Phase 1 study looked at how a new drug called KP-001 interacts with other medications in 38 healthy adults. The study measured how KP-001 affects the body's processing of rosuvastatin (a cholesterol drug) and caffeine, and how fluvoxamine (an antidepressant) affect…
Phase 1 • Sponsor: Kaken Pharmaceutical • Aim: Knowledge-focused
Last updated Jun 26, 2026 15:29 UTC